Cargando…
A Randomized Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Recombinant Erwinia Asparaginase (JZP‐458) in Healthy Adult Volunteers
L‐asparaginase has been an important component of acute lymphoblastic leukemia (ALL) therapy for over 40 years, and is standard therapy during ALL induction and consolidation treatment. L‐asparaginases are immunogenic and can induce hypersensitivity reactions; inability to receive asparaginase has b...
Autores principales: | Lin, Tong, Hernandez‐Illas, Martha, Rey, Andres, Jenkins, Jack, Chandula, Reddy, Silverman, Jeffrey A., Choi, Mi Rim |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8212713/ https://www.ncbi.nlm.nih.gov/pubmed/33278328 http://dx.doi.org/10.1111/cts.12947 |
Ejemplares similares
-
Population pharmacokinetics of intramuscular recombinant Erwinia chrysanthemi asparaginase (JZP458) in patients with acute lymphoblastic leukemia
por: Lin, Tong, et al.
Publicado: (2023) -
Population Pharmacokinetic Model Development and Simulation for Recombinant Erwinia Asparaginase Produced in Pseudomonas fluorescens (JZP‐458)
por: Lin, Tong, et al.
Publicado: (2021) -
Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase 2/3 AALL1931 study
por: Maese, Luke, et al.
Publicado: (2023) -
Population pharmacokinetics of intravenous Erwinia asparaginase in pediatric acute lymphoblastic leukemia patients
por: Sassen, Sebastiaan D.T., et al.
Publicado: (2017) -
Improved pharmacokinetic and pharmacodynamic profile of a novel PEGylated native Erwinia chrysanthemi L-Asparaginase
por: Modi, Tapasvi, et al.
Publicado: (2021)